Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. (NCT05930275)
A Multi-country, Prospective, Post-marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn's Disease for 3 Years in Real-world Clinical Practice (UPlift)
🩺 Plain-English Summary (8th-Grade Level)
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Speed of onset and durability of effectiveness will be assessed. Upadacitinib is a drug approved for the treatment of CD. All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 1200 participants will be enrolled in approximately 230 sites across the world. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.
Who can join: Review the eligibility criteria below.
Location: Blacktown Hospital /ID# 258574 — Blacktown, New South Wales
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (180 Sites)
Showing the first 25 of 180 sites.
- Blacktown Hospital /ID# 258574 — Blacktown, New South Wales
- Macquarie University Hospital /ID# 268722 — Macquarie University, New South Wales
- Mater Misericordiae Limited /ID# 258535 — South Brisbane, Queensland
- Ibd Sa /Id# 268335 — Kurralta Park, South Australia
- The Queen Elizabeth Hospital /ID# 258536 — Woodville South, South Australia
- Monash Health - Monash Medical Centre /ID# 258538 — Clayton, Victoria
- The Alfred Hospital /ID# 258537 — Melbourne, Victoria
- Gastro Med EOOD /ID# 267777 — Pazardzhik, Plovdiv
- ET dr Nikolay Tsonev /ID# 267584 — Samokov, Sofia
- MC Higia HB /ID# 267575 — Sofiya, Sofia
- Umbal Kaspela /ID# 267562 — Plovdiv,
- Diagnostic consultative center Focus-5 /ID# 267576 — Sofia,
- Diagnostic consultative center Focus-5 /ID# 268600 — Sofia,
- AIPSMP dr Mirchev EOOD /ID# 267583 — Varna,
- MC Nadejda Femily EOOD /ID# 267585 — Varna,
- DCC Mladost M /ID# 267586 — Varna,
- Foothills Medical Centre /ID# 263475 — Calgary, Alberta
- Dr. J Siffledeen Profess Pract /ID# 262713 — Edmonton, Alberta
- Fraser Clinical Trials Inc /ID# 262347 — New Westminster, British Columbia
- University of Manitoba & Shared Health /ID# 265853 — Winnipeg, Manitoba
- Queen Elizabeth II Health Sciences Centre - Victoria General /ID# 262764 — Halifax, Nova Scotia
- Barrie GI Associates /ID# 268436 — Barrie, Ontario
- London Health Sciences Center- University Hospital /ID# 262693 — London, Ontario
- West GTA Endoscopy /ID# 262946 — Mississauga, Ontario
- Scott Shulman Medicine Professional Corporation /ID# 262060 — North Bay, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohn's Disease
- A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Birmingham, Alabama
- A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
- Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — San Francisco, California
- Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts
Explore by condition: All Crohn's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.